• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Enterobacteriaceae Infections - Pipeline Review, H2 2012 Product Image

Enterobacteriaceae Infections - Pipeline Review, H2 2012

  • ID: 2298734
  • October 2012
  • 124 pages
  • Global Markets Direct

Enterobacteriaceae Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Enterobacteriaceae Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Enterobacteriaceae Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Enterobacteriaceae Infections. Enterobacteriaceae Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Enterobacteriaceae Infections.
- A review of the Enterobacteriaceae READ MORE >

2
List of Tables 8
List of Figures 9
Introduction 10
REPORT COVERAGE 10
Enterobacteriaceae Infections Overview 11
Therapeutics Development 12
An Overview of Pipeline Products for Enterobacteriaceae Infections 12
Enterobacteriaceae Infections Therapeutics under Development by Companies 14
Enterobacteriaceae Infections Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Enterobacteriaceae Infections Therapeutics – Products under Development by Companies 23
Enterobacteriaceae Infections Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Enterobacteriaceae Infections Therapeutics Development 25
AlphaRx, Inc. 25
GlaxoSmithKline plc 26
Bioniche Life Sciences, Inc. 27
Genentech, Inc. 28
Emergent BioSolutions Inc. 29
Nanotherapeutics, Inc. 30
Rib-X Pharmaceuticals, Inc. 31
Novartis AG 32
Cubist Pharmaceuticals, Inc. 33
Affinium Pharmaceuticals, Inc. 34
Orchid Chemicals & Pharmaceuticals Ltd 35
Thallion Pharmaceuticals Inc. 36
Achaogen Inc. 37
Bharat Biotech International Limited 38
Evolva SA 39
GlycoVaxyn AG 40
Variation Biotechnologies, Inc. 41
Phico Therapeutics Ltd. 42
Cantab Biopharmaceuticals Limited 43
Enterobacteriaceae Infections – Therapeutics Assessment 44
Assessment by Monotherapy Products 44
Assessment by Combination Products 45
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
plazomicin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ciprofloxacin - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
ACHN-975 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
GelVac - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
RX-04 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
EV-021 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ACE-920 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
GSK-2251052 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
EV-009 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
GVXN-SD133 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LED-209 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
WRSS-1 Vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Salmonella Typhi Vi O-acetyl Pectin-rEPA Conjugate Vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Invaplex 50 Vaccine - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Vi-rEPA(2) Conjugate Vaccine + DTP Vaccine - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CVD-1902 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
SC-599 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Typhella - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Vi-CRM197 Glycoconjugated Vaccine - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
ETEC Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AMR-BAC-2 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
AMR-BAC-3 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
SLP-0907 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 77
SLP-0901 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 79
FB-1811 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
WRSs2 + WRSs3 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Oral Shigella Vaccine - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Fabl Inhibitor Program - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
ETEC Adhesin-Based Vaccine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
dscCfaE + LTR192G - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
SASPject PT3.X - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Anti-Bacterial Program - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Shigamabs - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Typhoid TT Vaccine - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Inactivated whole cell shigella flexneri 2a vaccine - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
OCID5090 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
EV-035 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
RX-P792 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Shigella Vaccine - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
ExPEC Vaccine - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Gram-Negative Programme - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
ACHN-978 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Snare Antibacterial For Gram Negative Infections - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
Vi-CRM197 PCMV - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
CB-027 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
Carbavance - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Enterobacteriaceae Infections Therapeutics – Drug Profile Updates 104
Enterobacteriaceae Infections Therapeutics – Discontinued Products 111
Enterobacteriaceae Infections Therapeutics - Dormant Products 112
Enterobacteriaceae Infections – Product Development Milestones 113
Featured News & Press Releases 113
Sep 12, 2012: Merck Announces Presentation Of Scientific Data On Investigational Agent MK-7655 At 52nd Annual ICAAC 113
Sep 12, 2012: Rib-X Pharma Presents Preclinical Studies With New Classes Of RX-04 Antibiotic Compounds At ICAAC 114
Sep 12, 2012: Phico Therapeutics Achieves Developmental Milestone In Fight Against Multidrug Resistant Bacteria Enzyme NDM-1 116
Sep 12, 2012: Phico Therapeutics Achieves Developmental Milestone In Fight Against Multidrug Resistant Bacteria Enzyme NDM-1 117
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CB-027 At ICAAC 2012 118
Sep 06, 2012: Cubist Pharma To Feature Antibiotic Drug Candidate CXA-201 At ICAAC 2012 119
Sep 05, 2012: Rib-X Pharma To Present Data On RX-04 Program At ICAAC 2012 119
May 09, 2012: Thallion And LFB Biotechnologies Report Positive Top-Line Results From Phase II SHIGATEC Trial At VTEC 2012 120
Feb 16, 2012: BARDA Awards Contract Worth Upto $67m For Development Of New Tetraphase Antibiotic 120
Jan 09, 2012: Thallion And LFB Complete Patient Enrollment In Phase II SHIGATEC Trial 121
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 123
Disclaimer 123

List of Tables
Number of Products Under Development for Enterobacteriaceae Infections, H2 2012 12
Products under Development for Enterobacteriaceae Infections – Comparative Analysis, H2 2012 13
Number of Products under Development by Companies, H2 2012 15
Number of Products under Development by Companies, H2 2012 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2012 18
Comparative Analysis by Late Stage Development, H2 2012 19
Comparative Analysis by Mid Clinical Stage Development, H2 2012 20
Comparative Analysis by Early Clinical Stage Development, H2 2012 21
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 22
Products under Development by Companies, H2 2012 23
Products under Investigation by Universities/Institutes, H2 2012 24
AlphaRx, Inc., H2 2012 25
GlaxoSmithKline plc, H2 2012 26
Bioniche Life Sciences, Inc., H2 2012 27
Genentech, Inc., H2 2012 28
Emergent BioSolutions Inc., H2 2012 29
Nanotherapeutics, Inc., H2 2012 30
Rib-X Pharmaceuticals, Inc., H2 2012 31
Novartis AG, H2 2012 32
Cubist Pharmaceuticals, Inc., H2 2012 33
Affinium Pharmaceuticals, Inc., H2 2012 34
Orchid Chemicals & Pharmaceuticals Ltd, H2 2012 35
Thallion Pharmaceuticals Inc., H2 2012 36
Achaogen Inc., H2 2012 37
Bharat Biotech International Limited, H2 2012 38
Evolva SA, H2 2012 39
GlycoVaxyn AG, H2 2012 40
Variation Biotechnologies, Inc., H2 2012 41
Phico Therapeutics Ltd., H2 2012 42
Cantab Biopharmaceuticals Limited, H2 2012 43
Assessment by Monotherapy Products, H2 2012 44
Assessment by Combination Products, H2 2012 45
Assessment by Stage and Route of Administration, H2 2012 47
Assessment by Stage and Molecule Type, H2 2012 49
Enterobacteriaceae Infections Therapeutics – Drug Profile Updates 104
Enterobacteriaceae Infections Therapeutics – Discontinued Products 111
Enterobacteriaceae Infections Therapeutics – Dormant Products 112

List of Figures
Number of Products under Development for Enterobacteriaceae Infections, H2 2012 12
Products under Development for Enterobacteriaceae Infections – Comparative Analysis, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 17
Late Stage Products, H2 2012 19
Mid Clinical Stage Products, H2 2012 20
Early Clinical Stage Products, H2 2012 21
Discovery and Pre-Clinical Stage Products, H2 2012 22
Assessment by Monotherapy Products, H2 2012 44
Assessment by Combination Products, H2 2012 45
Assessment by Route of Administration, H2 2012 46
Assessment by Stage and Route of Administration, H2 2012 47
Assessment by Molecule Type, H2 2012 48
Assessment by Stage and Molecule Type, H2 2012 49

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos